California Launched a Large-Scale Program to Study THC for Cancer Patients Across Ages
California designed four separate protocols to study optimal THC and marijuana dosing for nausea control in cancer patients, including children, elderly patients, and those receiving long-term treatment.
Quick Facts
What This Study Found
Recognizing that existing THC studies left major questions unanswered, California established a statewide program combining therapeutic access with structured research.
Four protocols were designed to address specific gaps: optimal oral THC dosing in adults on cyclic chemotherapy, optimal dosing in children, dosing for adults on chronic chemotherapy or radiation therapy, and optimal dosing for smoked marijuana. Each protocol would track side effects and efficacy by chemotherapy agent, cancer type, age, and sex.
The program was notable for its scale, involving over 200 investigators, and for explicitly studying populations often excluded from cannabis research: pediatric patients, elderly patients, and the very ill. The researchers acknowledged the substantial challenges of running a large collaborative study with community practitioners while maintaining scientific rigor.
Key Numbers
Four separate protocols. Over 200 investigators. Populations included: adults on cyclic chemotherapy, children, adults on chronic chemotherapy or radiotherapy, and smoked marijuana users.
How They Did This
Description of a multi-protocol statewide research program. Four separate protocols covered different patient populations and administration routes. Over 200 investigators participated across community practice settings.
Why This Research Matters
This was one of the first large-scale, government-sponsored efforts to study therapeutic cannabis use in real-world medical settings. Its inclusion of children, elderly patients, and multiple cancer types addressed critical gaps in the evidence base that small academic studies had not covered.
The Bigger Picture
The California program represented an early model of pragmatic clinical research, combining therapeutic access with data collection in a way that foreshadowed modern medical cannabis programs. Its challenges, particularly maintaining research quality across hundreds of community practitioners, remain relevant to cannabis research today.
What This Study Doesn't Tell Us
The abstract describes the program design rather than results. Phase III collaborative studies across community practices inherently involve less control than academic clinical trials. The emphasis on broad access may have complicated rigorous data collection.
Questions This Raises
- ?What results did these protocols ultimately produce?
- ?How well did the community practitioner model work for maintaining data quality?
- ?Did the pediatric and geriatric findings differ meaningfully from adult results?
Trust & Context
- Key Stat:
- Over 200 investigators participated in the statewide research program
- Evidence Grade:
- A program description and protocol design paper, not a results publication. Provides important historical context but no efficacy or safety data.
- Study Age:
- Published in 1981. Modern medical cannabis programs have evolved substantially from this early model.
- Original Title:
- The California program for the investigational use of THC and marihuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapy.
- Published In:
- Journal of clinical pharmacology, 21(S1), 128S-132S (1981)
- Authors:
- Dow, G J, Meyers, F H
- Database ID:
- RTHC-00018
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Did this program study children?
Yes. One of the four protocols was specifically designed to determine optimal oral THC dosing in pediatric cancer patients.
Was this about smoked marijuana or pills?
Both. Three protocols studied oral THC and one protocol specifically studied smoked marijuana dosing.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-cancer-pain-beyond-chemo-nausea
Cite This Study
https://rethinkthc.com/research/RTHC-00018APA
Dow, G J; Meyers, F H. (1981). The California program for the investigational use of THC and marihuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapy.. Journal of clinical pharmacology, 21(S1), 128S-132S.
MLA
Dow, G J, et al. "The California program for the investigational use of THC and marihuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapy.." Journal of clinical pharmacology, 1981.
RethinkTHC
RethinkTHC Research Database. "The California program for the investigational use of THC an..." RTHC-00018. Retrieved from https://rethinkthc.com/research/dow-1981-the-california-program-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.